Last reviewed · How we verify
Bibrocathin (BIBROCATHOL)
Bibrocathin (generic name: BIBROCATHOL) is a bibrocathol drug. It is currently in Phase 2 development.
Bibrocathol is thought to work by inhibiting a specific enzyme or receptor, although the exact details of its mechanism are not well understood.
Bibrocathol is a small molecule drug in the bibrocathol class, developed by an unknown entity and currently owned by an unknown entity. Its target and exact mechanism of action are not specified. Bibrocathol is not FDA-approved for any indications, and its commercial status, half-life, bioavailability, generic manufacturers, and patent status are unknown. As a result, there is limited information available on its safety profile and clinical use. Further research is needed to determine the potential therapeutic applications and risks associated with bibrocathol.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BIBROCATHOL |
|---|---|
| Drug class | bibrocathol |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have a specific lock on the door, and bibrocathol is a key that fits into that lock. When it binds to the lock, it prevents other molecules from entering or leaving the cell, which can affect how the cell functions. This can be useful in treating certain diseases, but it's a complex process that requires more research to fully understand.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bibrocathin CI brief — competitive landscape report
- Bibrocathin updates RSS · CI watch RSS
Frequently asked questions about Bibrocathin
What is Bibrocathin?
How does Bibrocathin work?
What is the generic name of Bibrocathin?
What drug class is Bibrocathin in?
What development phase is Bibrocathin in?
Related
- Drug class: All bibrocathol drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing